Soleno Therapeutics (SLNO) Change in Cash (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Change in Cash data on file, last reported at $62.9 million in Q1 2026.

• On a quarterly basis, Change in Cash rose 1053.77% year-over-year to $62.9 million in Q1 2026; TTM through Mar 2026 was $51.7 million, a 34.33% increase from a year earlier, with the FY2025 full-year figure at -$17.8 million, up 78.2% from the prior year.
• Change in Cash for Q1 2026 stood at $62.9 million, up from -$176.6 million in the prior quarter.
• Over the last five years, Change in Cash for SLNO reached as high as $170.2 million in Q3 2025 and fell as low as -$176.6 million in Q4 2025.
• Historically, Change in Cash has averaged $6.6 million across 5 years, with a median of -$1.2 million in 2022.
• Across the five-year window, Change in Cash jumped 2837.5% in 2023 and slumped 1785.17% in 2024, its largest moves.
• Year by year, Change in Cash stood at -$8.3 million in 2022, then soared by 1520.28% to $117.2 million in 2023, then slumped by 66.3% to $39.5 million in 2024, then plunged by 546.81% to -$176.6 million in 2025, then jumped by 135.64% to $62.9 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were $62.9 million in Q1 2026, -$176.6 million in Q4 2025, and $170.2 million in Q3 2025.